e-ISSN: 2321-3647
logo

American Journal of Pharmacy and Health Research

LoginTrack

📢 Latest Update: Call for Papers – Special Issue on Pharmacy and Health Research (April 2026 Submission Deadline)

📢 Latest Update: Call for Papers – Special Issue on Pharmacy and Health Research (April 2026 Submission Deadline)

Volume 13, Issue 7 - 2025 (July 2025 Issue 07)

Volume 13 Issue 7 Cover

Issue Details:

Volume 13 Issue 7
Published:Invalid Date

Editorial: July 2025 Issue 07

Welcome to the 2025 issue of American Journal of Pharmacy and Health Research. This issue showcases the remarkable breadth and depth of contemporary research across multiple disciplines. From cutting-edge applications of machine learning in climate science to the revolutionary potential of quantum computing in drug discovery, our featured articles demonstrate the power of interdisciplinary collaboration in addressing global challenges.

We are particularly excited to present research that bridges traditional academic boundaries, reflecting our journal's commitment to fostering innovation through cross-disciplinary dialogue. The integration of artificial intelligence with environmental science, the application of blockchain technology to supply chain management, and the convergence of urban planning with smart city technologies exemplify the transformative potential of collaborative research.

As we continue to navigate an era of rapid technological advancement and global challenges, the research presented in this issue offers both insights and solutions that will shape our future. We thank our authors, reviewers, and editorial board members for their continued dedication to advancing knowledge and promoting scientific excellence.

Dr. Hemangi J Patel
Editor-in-Chief
American Journal of Pharmacy and Health Research

Articles in This Issue

Showing 3 of 3 articles
Research PaperID: AJPHR1307001

A Review On Infectious Diseases Pharmacology

K Malleswari, DR.D. Rama Brahma Reddy, Shaik Shairabhanu, S Venkata Naveena, SD. Ruksana parveen

ABSTRACTInfectious diseases caused 13.2 million deaths in 2023, with antimicrobial resistance (AMR) contributing 1.3 million deaths annually and posing a $100 trillion economic threat by 2050. This review explores advancements in infectious diseases pharmacology, including AMR mechanisms, novel therapeutics, pharmacokinetics/pharmacodynamics (PK/PD), antimicrobial stewardship, genomic surveillance, artificial intelligence (AI) in drug discovery, global health policies, pandemic preparedness, vaccine development, One Health approaches, and clinical case studies. Innovations like cefiderocol, mRNA vaccines, bacteriophage therapies, and AI-driven drug design, supported by clinical trials, address resistant pathogens. Images of diseases like tuberculosis, Candida auris, and MRSA, integrated within relevant sections, enhance clinical understanding. Integrated strategies are vital to combat AMR and improve global health. Keywords: Infectious diseases, Antimicrobial resistance (AMR), Pharmacology, Novel therapeutics, Pharmacokinetics/pharmacodynamics (PK/PD), Artificial intelligence (AI), Antimicrobial stewardship, Vaccine development, Genomic surveillance, One Health

Infectious diseasesAntimicrobial resistance (AMR)PharmacologyNovel therapeuticsPharmacokinetics/pharmacodynamics (PK/PD)Artificial intelligence (AI)+4 more
110,960 views
33,209 downloads
DOI:
10.5281/zenodo.16924985

Contributors:

 K Malleswari
,
 DR.D. Rama Brahma Reddy
,
 Shaik Shairabhanu
,
 S Venkata Naveena
,
 SD. Ruksana parveen
Research PaperID: AJPHR1307002

Development and Validation of A Robust RP-HPLC Method For Simultaneous Estimation of Telmisartan and Cilnidipine In Bulk and Tablet Dosage Form

Anna Pratima G. Nikalje, Swati Mahadeo Andhale

ABSTRACTA simple, accurate, precise, and cost-effective reversed-phase high-performance liquid chromatography (RP-HPLC) method has been developed and validated for the simultaneous estimation of Telmisartan and Cilnidipine in bulk and marketed tablet dosage form. Chromatographic separation was achieved using an Agilent C18 column (250mm × 4.6mm, 5 ?m) with a mobile phase consisting of Acetonitrile and phosphate buffer (pH 3.0) in a 90:10 v/v ratio, at a flow rate of 1.0 mL/min and detection wavelength of 254 nm. Method validation followed ICH Q2 (R1) guidelines for system suitability, linearity, accuracy, precision, robustness, LOD, and LOQ. The method showed linearity over the range of 40–240 ?g/mL for Telmisartan and 10–60 ?g/mL for Cilnidipine, with correlation coefficients (R²) of 0.9998 for both drugs. The method was found to be accurate, precise (%RSD < 2%), robust, and suitable for routine quality control analysis in pharmaceutical formulations. Keywords: Telmisartan, Cilnidipine, RP-HPLC, Method Validation, ICH Q2(R1), Fixed-Dose Combination

TelmisartanCilnidipineRP-HPLCMethod ValidationICH Q2(R1)Fixed-Dose Combination
111,102 views
33,289 downloads
DOI:
10.5281/zenodo.16925001

Contributors:

 Anna Pratima G. Nikalje
,
 Swati Mahadeo Andhale
Research PaperID: AJPHR1307003

Blood-Brain Delivery Methods Using Nanotechnology

K. Malleswari, D Rama Brahma Reddy, U Akhila, V Baby Naga Lakshmi

ABSTRACTBlood–brain barrier (BBB) is a natural protective membrane that prevents central nervous system (CNS) from toxins and pathogens in blood. However, the presence of BBB complicates the pharmacotherapy for CNS disorders as the most chemical drugs and biopharmaceuticals have been impeded to enter the brain. Insufficient drug delivery into the brain leads to low therapeutic efficacy as well as aggravated side effects due to the accumulation in other organs and tissues. Nanotechnology-enabled drug delivery systems have emerged as a promising tool for overcoming the Blood Brain Barrier (BBB) and delivering drugs to the Central Nervous System (CNS). This mini-review provides an overview of recent advancements in nanotechnology to improve blood-brain barrier penetration. It covers different approaches, such as using targeted ligands and receptors, engineered carriers and transporters, and surface modifications for targeting the blood-brain barrier. Polymeric nanoparticles, liposomes, and metallic nanoparticles, such as silver and zinc oxide, are discussed in the context of their unique properties and applications. Preclinical and clinical advances in nanotechnology-based BBB delivery are discussed, including transcellular nanotechnology-based brain drug delivery and preclinical and clinical studies of nanocarriers for CNS disorders. Although nanotechnology has shown great potential for treating CNS diseases, several challenges remain. The major challenges and future perspectives for constructing brain-targeted delivery systems are also discussed, particularly limitations associated with the blood-brain barrier and clinical obstacles to CNS disease treatment. Keywords: Nanoparticles; Blood brain barrier; Drug delivery systems; engineered carriers, Alzheimer disease, Liposomes.

NanoparticlesBlood brain barrierDrug delivery systemsengineered carriersAlzheimer diseaseLiposomes
110,895 views
33,386 downloads
DOI:
10.5281/zenodo.16925014

Contributors:

 K. Malleswari
,
 D Rama Brahma Reddy
,
 U Akhila
,
 V Baby Naga Lakshmi

Related Issues

Volume 14, Issue 4

2026 • 0 articles

Volume 14, Issue 3Current

2026 • 3 articles

Volume 14, Issue 2

2026 • 2 articles

Volume 14, Issue 1

2026 • 2 articles